Spondyloarthritis & psoriatic arthritis
Effectiveness of TNF inhibitors in patients with very early axial spondyloarthritis, defined as duration of ≤1 year of back pain: longitudinal observational data from the SCQM registry
Main finding · ASDAS <2.1Result — go to the resultOdds ratio 1.08 95% CI 0.70–1.68Authors' conclusion
We found no evidence for a better effectiveness of TNFi in patients with very early versus established axSpA.
Study context
- Population
- Patients with axial spondyloarthritis (axSpA) in the Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) registry with available data on duration of back pain
- Participants
- 3,324 patients
- Exposure
- First tumour necrosis factor inhibitor (TNFi) in very early vs established axSpA
- Very early axSpAn = 441
- Early axSpAn = 218
- Established axSpAn = 2,575reference
- Outcome
- Low disease activity (ASDAS <2.1) after a first TNFi
- Follow-up
- 1 year
Methodological detailslongitudinal observational registry, multiple-adjusted, multiple imputation by chained equations
- Longitudinal observational registry
- Multiple-adjusted
- Multiple imputation by chained equations
Main finding
ASDAS <2.1
Odds ratio
1.08
95% CI 0.70–1.68
Very early axSpAvs Established axSpA
OR 1.08 (95% CI 0.70–1.68)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| TNFi drug discontinuation (retention)Very early axSpAvs Established axSpA | 1.05 (0.84–1.31) | |
| 0.512Hazard ratio (log scale) |
First TNFi started
Objective signs of inflammation
- More prevalent in very early disease
Original publication
Effectiveness of TNF inhibitors in patients with very early axial spondyloarthritis, defined as duration of ≤1 year of back pain: longitudinal observational data from the SCQM registry. RMD Open. Published 5 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →